These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

235 related items for PubMed ID: 8176463

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Cutoff value of thyroid uptake of (99m)Tc-pertechnetate to discriminate between Graves' disease and painless thyroiditis: a single center retrospective study.
    Uchida T, Suzuki R, Kasai T, Onose H, Komiya K, Goto H, Takeno K, Ishii S, Sato J, Honda A, Kawano Y, Himuro M, Yamada E, Yamada T, Watada H.
    Endocr J; 2016; 63(2):143-9. PubMed ID: 26581846
    [Abstract] [Full Text] [Related]

  • 25. The mechanism of spontaneous hypothyroidism in patients with Graves' disease after antithyroid drug treatment.
    Tamai H, Hirota Y, Kasagi K, Matsubayashi S, Kuma K, Iida Y, Konishi J, Okimura MC, Walter RM, Kumagai LF.
    J Clin Endocrinol Metab; 1987 Apr; 64(4):718-22. PubMed ID: 2434520
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Thyroid-stimulating antibodies in patients with autoimmune disorders.
    Strakosch CR, Joyner D, Wall JR.
    J Clin Endocrinol Metab; 1978 Aug; 47(2):361-5. PubMed ID: 263731
    [Abstract] [Full Text] [Related]

  • 28. Relapse of Graves' disease after medical therapy: predictive value of thyroidal technetium-99m uptake and serum thyroid stimulating hormone receptor antibody levels.
    Wilson R, McKillop JH, Pearson DW, Cuthbert GF, Thomson JA.
    J Nucl Med; 1985 Sep; 26(9):1024-8. PubMed ID: 2863338
    [Abstract] [Full Text] [Related]

  • 29. Prediction of remission in Graves' disease treated with long-term carbimazole therapy: evaluation of technetium-99m thyroid uptake and TSH concentrations as prognostic indicators.
    Prakash R.
    Eur J Nucl Med; 1996 Feb; 23(2):118-22. PubMed ID: 8925844
    [Abstract] [Full Text] [Related]

  • 30. Development of spontaneous hypothyroidism in patients with Graves' disease treated with antithyroidal drugs: clinical, immunological, and histological findings in 26 patients.
    Tamai H, Kasagi K, Takaichi Y, Takamatsu J, Komaki G, Matsubayashi S, Konishi J, Kuma K, Kumagai LF, Nagataki S.
    J Clin Endocrinol Metab; 1989 Jul; 69(1):49-53. PubMed ID: 2471711
    [Abstract] [Full Text] [Related]

  • 31. Differences between changes in serum thyrotropin-binding inhibitory antibodies and thyroid-stimulating antibodies in the course of antithyroid drug therapy for Graves' disease.
    Yamano Y, Takamatsu J, Sakane S, Hirai K, Kuma K, Ohsawa N.
    Thyroid; 1999 Aug; 9(8):769-73. PubMed ID: 10482368
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. [Occurrence of immune hyperthyroidism after radioiodine therapy of autonomous goiter].
    Hirsch C, Spyra JL, Langhammer HR, Laubenbacher C, Senekowitsch-Schmidtke R, Schwaiger M.
    Med Klin (Munich); 1997 Mar 15; 92(3):130-7. PubMed ID: 9173203
    [Abstract] [Full Text] [Related]

  • 34. Hypothyroidism during antithyroid drug treatment with methimazole is a favorable prognostic indicator in patients with Graves' disease.
    Choo YK, Yoo WS, Kim DW, Chung HK.
    Thyroid; 2010 Sep 15; 20(9):949-54. PubMed ID: 20629556
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. A sensitive and practical assay for thyroid-stimulating antibodies using crude immunoglobulin fractions precipitated with polyethylene glycol.
    Kasagi K, Konishi J, Arai K, Misaki T, Iida Y, Endo K, Torizuka K.
    J Clin Endocrinol Metab; 1986 May 15; 62(5):855-62. PubMed ID: 2870075
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Thyroid histology of hyperthyroid Graves' disease with undetectable thyrotropin receptor antibodies.
    Kawai K, Tamai H, Mori T, Morita T, Matsubayashi S, Katayama S, Kuma K, Kumagai LF.
    J Clin Endocrinol Metab; 1993 Sep 15; 77(3):716-9. PubMed ID: 7690362
    [Abstract] [Full Text] [Related]

  • 40. Standardized grey scale ultrasonography in Graves' disease: correlation to autoimmune activity.
    Schiemann U, Gellner R, Riemann B, Schierbaum G, Menzel J, Domschke W, Hengst K.
    Eur J Endocrinol; 1999 Oct 15; 141(4):332-6. PubMed ID: 10526244
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.